Cell-free DNA as a biomarker in cancer

Abstract

Translational research of liquid biopsy is just at the edge of routine clinical application: an emerging validity of circulating tumor DNA (ctDNA) tests suggests its use for earlier cancer detection and better monitoring of minimal residual disease (MRD) and resistance development, thus offering earlier guidance for therapy choices with the intent to cure cancer. In this review, we focus on ctDNA as an advanced and standardized validated marker in liquid biopsy. We also discuss what will be needed to reach the new milestone of personalized (precision) medicine to be used as a common standard of care. We summarize recent developments of cell-free DNA (cfDNA) and its clinical use as a biomarker in cancer.

Keywords

Cell-free DNA / cfDNA / circulating tumor DNA / ctDNA / biomarker / liquid biopsy / MRD / cancer

References

[1] SMART. Servier Med Art. Available from: https://smart.servier.com/ [Last accessed on April 5, 2022]

[2] Creative Commons - Attribution 3.0 Unported - CC BY 3.0. Available from: https://creativecommons.org/licenses/by/3.0/ [Last accessed on April 5, 2022]

[3] Ashworth A.A case of cancer in which cells similar to those in the tumours were seen in the blood after death.Aust Med J1869;14:146

[4] Paget S.The distribution of secondary growths in cancer of the breast.The Lancet1889;133:571-3

[5] Mandel P.Nuclear acids in human blood plasma.CR Seances Soc Biol Fil1948;142:241-3.

[6] Fidler IJ.Biological behavior of malignant melanoma cells correlated to their survival in vivo.Cancer Res1975;35:218-24.

[7] Leon SA,Sklaroff DM.Free DNA in the serum of cancer patients and the effect of therapy.Cancer Res1977;37:646-50.

[8] Lo Y,Gillmer M,Sampietro M.Prenatal sex determination by DNA amplification from maternal peripheral blood.The Lancet1989;334:1363-5.

[9] Reya T,Clarke MF.Stem cells, cancer, and cancer stem cells.Nature2001;414:105-11.

[10] Balaña C,Taron M.O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme.Clin Cancer Res2003;9:1461-8.

[11] Allard WJ,Miller MC.Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases.Clin Cancer Res2004;10:6897-904.

[12] Cristofanilli M,Ellis MJ.Circulating tumor cells, disease progression, and survival in metastatic breast cancer.N Engl J Med2004;351:781-91

[13] Diehl F,Dressman D.Detection and quantification of mutations in the plasma of patients with colorectal tumors.Proc Natl Acad Sci USA2005;102:16368-73. PMCID:PMC1283450

[14] Maheswaran S,Nagrath S.Detection of mutations in EGFR in circulating lung-cancer cells.N Engl J Med2008;359:366-77 PMCID:PMC3551471

[15] Diehl F,Choti MA.Circulating mutant DNA to assess tumor dynamics.Nat Med2008;14:985-90 PMCID:PMC2820391

[16] Cohen SJ,Iannotti N.Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.J Clin Oncol2008;26:3213-21

[17] de Bono JS,Montgomery RB.Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.Clin Cancer Res2008;14:6302-9

[18] Pantel K.Circulating tumour cells in cancer patients: challenges and perspectives.Trends Mol Med2010;16:398-406

[19] Calverley DC,Choudhury QG.Significant downregulation of platelet gene expression in metastatic lung cancer.Clin Transl Sci2010;3:227-32 PMCID:PMC3427741

[20] Dawson SJ,Murtaza M.Analysis of circulating tumor DNA to monitor metastatic breast cancer.N Engl J Med2013;368:1199-209

[21] Bettegowda C,Leary RJ.Detection of circulating tumor DNA in early- and late-stage human malignancies.Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[22] Sullivan JP,Madden MW.Brain tumor cells in circulation are enriched for mesenchymal gene expression.Cancer Discov2014;4:1299-309 PMCID:PMC4221467

[23] Mazel M,Pantel K.Frequent expression of PD-L1 on circulating breast cancer cells.Mol Oncol2015;9:1773-82 PMCID:PMC5528721

[24] Tie J,Tomasetti C.Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.Sci Transl Med2016;8:346ra92 PMCID:PMC5346159

[25] Donaldson J.Circulating tumor DNA: measurement and clinical utility.Annu Rev Med2018;69:223-34

[26] Cohen JD,Wang Y.Detection and localization of surgically resectable cancers with a multi-analyte blood test.Science2018;359:926-30 PMCID:PMC6080308

[27] Lennon AM,Kinde I.Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.Science2020;369:eabb9601 PMCID:PMC7509949

[28] Romero D.Tracking cancer in liquid biopsies. Nat Res 2022.. PMCID:PMC8910330

[29] Research C for DE and.cobas EGFR Mutation Test v2.FDA2018;

[30] Alix-Panabières C.Liquid biopsy: from discovery to clinical application.Cancer Discov2021;11:858-73

[31] Eibl RH.Liquid biopsy and primary brain tumors.Cancers (Basel)2021;13:5429 PMCID:PMC8582521

[32] Feng D,Li K.CircZNF609 promotes bladder cancer progression and inhibits cisplatin sensitivity via miR-1200/CDC25B pathway. 2022.

[33] Bardelli A.Liquid biopsies: what we do not know (yet).Cancer Cell2017;31:172-9 PMCID:PMC5016094

[34] Louis DN,Reifenberger G.The 2016 World Health Organization classification of tumors of the central nervous system: a summary.Acta Neuropathol2016;131:803-20

[35] Müller NL,Miller RR.Seeding of malignant cells into the needle track after lung and pleural biopsy.Can Assoc Radiol J1986;37:192-4

[36] Joosse SA,Gasch C.Tumor-associated release of prostatic cells into the blood after transrectal ultrasound-guided biopsy in patients with histologically confirmed prostate cancer.Clin Chem2020;66:161-8

[37] Eslami-S Z,Cayrefourcq L.The different facets of liquid biopsy: a kaleidoscopic view.Cold Spring Harb Perspect Med2020;10:a037333 PMCID:PMC7263091

[38] Kuske A,Tennstedt P.Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.Sci Rep2016;6:39736 PMCID:PMC5175156

[39] Ramirez JM,Orsini M.Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients.Clin Chem2014;60:214-21

[40] Cayrefourcq L,Garcia C.S100-EPISPOT: a new tool to detect viable circulating melanoma cells.Cells2019;8:755 PMCID:PMC6678250

[41] Mazard T,Perriard F.Clinical relevance of viable circulating tumor cells in patients with metastatic colorectal cancer: the COLOSPOT prospective study.Cancers (Basel)2021;13:2966 PMCID:PMC8231886

[42] Garrel R,Perriard F.Circulating tumor cells as a prognostic factor in recurrent or metastatic head and neck squamous cell carcinoma: the CIRCUTEC prospective study.Clin Chem2019;65:1267-75

[43] Denève E,Ramos J.Capture of viable circulating tumor cells in the liver of colorectal cancer patients.Clin Chem2013;59:1384-92

[44] Cayrefourcq L,Joosse S.Establishment and characterization of a cell line from human circulating colon cancer cells.Cancer Res2015;75:892-901

[45] Alix-Panabières C.Circulating tumor cells: liquid biopsy of cancer.Clin Chem2013;59:110-8

[46] Koch C,Joosse SA.Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.EMBO Mol Med2020;12:e11908 PMCID:PMC7507517

[47] Neuberger EWI,Brahmer A.Physical activity specifically evokes release of cell-free DNA from granulocytes thereby affecting liquid biopsy.Clin Epigenetics2022;14:29 PMCID:PMC8864902

[48] Lo YMD,Jiang P.Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies.Science2021;372:eaaw3616

[49] Kwapisz D.The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer?.Ann Transl Med2017;5:46 PMCID:PMC5326656

[50] Misale S,Hobor S.Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer.Nature2012;486:532-6 PMCID:PMC3927413

[51] Diaz LA Jr,Wu J.The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers.Nature2012;486:537-40 PMCID:PMC3436069

[52] André F,Rubovszky G.SOLAR-1 Study GroupAlpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer.N Engl J Med2019;380:1929-40

[53] Preuss I,Haas S.O6-methylguanine-DNA methyltransferase activity in breast and brain tumors.Int J Cancer1995;61:321-6

[54] Preuss I,Eichhorn U.Activity of the DNA repair protein O6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue.Cancer Detect Prev1996;20:130-6.

[55] Song CX,Ma L.5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages.Cell Res2017;27:1231-42 PMCID:PMC5630676

[56] Heitzer E,Roberts CES.Current and future perspectives of liquid biopsies in genomics-driven oncology.Nat Rev Genet2019;20:71-88

[57] Ignatiadis M,Jeffrey SS.Liquid biopsy enters the clinic - implementation issues and future challenges.Nat Rev Clin Oncol2021;18:297-312

[58] Jiang P,Chan KC.Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients.Proc Natl Acad Sci USA2015;112:E1317-25 PMCID:PMC4372002

[59] Serpas L,Jiang P.Dnase1l3 deletion causes aberrations in length and end-motif frequencies in plasma DNA.Proc Natl Acad Sci USA2019;116:641-9 PMCID:PMC6329986

[60] Jiang P,Peng W.Plasma DNA end-motif profiling as a fragmentomic marker in cancer, pregnancy, and transplantation.Cancer Discov2020;10:664-73

[61] Kitano Y,Ohka F.Urinary microRNA-based diagnostic model for central nervous system tumors using nanowire scaffolds.ACS Appl Mater Interfaces2021;13:17316-29

[62] Chen WW,Liau LM.BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles.Mol Ther Nucleic Acids2013;2:e109 PMCID:PMC3732870

[63] Best MG,Kooi I.RNA-Seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics.Cancer Cell2015;28:666-76 PMCID:PMC4644263

[64] Best MG,Wurdinger T.Tumor-educated platelets as a noninvasive biomarker source for cancer detection and progression monitoring.Cancer Res2018;78:3407-12

[65] Home - ClinicalTrials. gov. Available from: https://www.clinicaltrials.gov/ [Last accessed on 27 Jul 2022]

[66] Garcia-Murillas I,Weigelt B.Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer.Sci Transl Med2015;7:302ra133

[67] Olsson E,George A.Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease.EMBO Mol Med2015;7:1034-47 PMCID:PMC4551342

[68] Phallen J,Adleff V.Direct detection of early-stage cancers using circulating tumor DNA.Sci Transl Med2017;9:eaan2415 PMCID:PMC6714979

[69] Abbosh C,Wilson GA.The TRACERx consortiumThe PEACE consortiumPhylogenetic ctDNA analysis depicts early-stage lung cancer evolution.Nature2017;545:446-51

[70] Ng SB,Ng M.Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery.Sci Rep2017;7:40737 PMCID:PMC5244357

[71] Schøler LV,Ørntoft MW.Clinical implications of monitoring circulating tumor DNA in patients with colorectal cancer.Clin Cancer Res2017;23:5437-45

[72] Chaudhuri AA,Lovejoy AF.Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling.Cancer Discov2017;7:1394-403 PMCID:PMC5895851

[73] Mehra N,Sumanasuriya S.Plasma cell-free DNA concentration and outcomes from taxane therapy in metastatic castration-resistant prostate cancer from two phase III trials (FIRSTANA and PROSELICA).European Urology2018;74:283-91 PMCID:PMC6090941

[74] Annala M,Khalaf D.Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer.Cancer Discov2018;8:444-57

[75] Coombes RC,Salari R.Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence.Clin Cancer Res2019;25:4255-63

[76] Garcia-Murillas I,Comino-Méndez I.Assessment of molecular relapse detection in early-stage breast cancer.JAMA Oncol2019;5:1473-8 PMCID:PMC6681568

[77] Moding EJ,Nabet BY.Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer.Nat Cancer2020;1:176-83 PMCID:PMC8425388

[78] McDuff SGR,Ulintz PJ.Circulating tumor DNA predicts pathologic and clinical outcomes following neoadjuvant chemoradiation and surgery for patients with locally advanced rectal cancer.JCO Precis Oncol2021;5:PO PMCID:PMC8232395

[79] Taniguchi H,Kotani D.CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.Cancer Sci2021;112:2915-20 PMCID:PMC8253296

[80] Gale D,Ruiz-Valdepenas A.Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer.Ann Oncol2022;33:500-10 PMCID:PMC9067454

[81] Tie J,Lahouel K.DYNAMIC InvestigatorsCirculating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.N Engl J Med2022;386:2261-72

[82] Ohgaki H,Wiestler OD,Newcomb EW.p53 mutations in nonastrocytic human brain tumors.Cancer Res1991;51:6202-5.

[83] Zhukova N,Remke M.Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.J Clin Oncol2013;31:2927-35 PMCID:PMC4878050

[84] Riva F,Houy A.Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer.Clin Chem2017;63:691-9

[85] Radovich M,Hancock BA.Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomized clinical trial.JAMA Oncol2020;6:1410-5 PMCID:PMC7349081

[86] MD BS. A Phase II Randomized controlled trial of genomically directed therapy after preoperative chemotherapy in patients with triple negative breast cancer: hoosier oncology group BRE12-158. clinicaltrials.gov 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT02101385 [Last accessed on 2 Aug 2022]

[87] University College, London. The SUMMIT study: cancer screening study with or without low dose lung CT to validate a multi-cancer early detection test. clinicaltrials.gov; 2021. Available from: https://www.clinicaltrials.gov/ct2/show/NCT03934866 [Last accessed on 28 Jul 2022]

[88] Technische Universität Dresden. Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation (CIRCULATE) AIO-KRK-0217. clinicaltrials.gov; 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04089631 [Last accessed on 2 Aug 2022]

[89] Hospices Civils de Lyon. The circTeloDIAG: a new approach of liquid biopsy for the diagnosis and follow-up of patients with glioma tumor. clinicaltrials.gov; 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT04931732 [Last accessed on 2 Aug 2022]

[90] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[91] Hennigan ST,Terrigino NT.Low abundance of circulating tumor DNA in localized prostate cancer.JCO Precis Oncol2019;3:PO.19.00176 PMCID:PMC6746181

[92] Lavon I,Zelikovitch B,Siegal T.Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades.Neuro Oncol2010;12:173-80 PMCID:PMC2940579

[93] Majchrzak-Celińska A,Kleszcz R.Detection of MGMT, RASSF1A, p15INK4B, and p14ARF promoter methylation in circulating tumor-derived DNA of central nervous system cancer patients.J Appl Genet2013;54:335-44 PMCID:PMC3720989

[94] Boisselier B,Rossetto M.Detection of IDH1 mutation in the plasma of patients with glioma.Neurology2012;79:1693-8

[95] Schwaederle M,Kato S.Genomic alterations in circulating tumor DNA from diverse cancer patients identified by next-generation sequencing.Cancer Res2017;77:5419-27 PMCID:PMC5626633

[96] Weaver KD,Herman JG.Methylated tumor-specific DNA as a plasma biomarker in patients with glioma.Cancer Invest2006;24:35-40

[97] Eibl RH. Induction of primitive neuroectodermal tumors following retrovirus-mediated transfer of SV40 large T antigen into neural transplants. Zülch symposium on growth control and neoplastic transformation in the brain. Goslar, Germany. Rockledge, U.S.A.: Dustri; 1991. pp. 248–9.

[98] Eibl RH,Jat PS.A model for primitive neuroectodermal tumors in transgenic neural transplants harboring the SV40 large T antigen.Am J Pathol1994;144:556-64 PMCID:PMC1887088

[99] Saylors RL,Friedman HS.Infrequent p53 gene mutations in medulloblastomas.Cancer Res1991;51:4721-3

[100] Kleihues P,Eibl RH.Type and frequency of p53 mutations in tumors of the nervous system and its coverings.Recent Results Cancer Res1994;135:25-31

[101] Louis DN,Chung RY.Comparative study of p53 gene and protein alterations in human astrocytic tumors.J Neuropathol Exp Neurol1993;52:31-8

[102] Ohgaki H,Schwab M.Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system.Mol Carcinog1993;8:74-80

[103] von Deimling A,Ohgaki H.p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma.Cancer Res1992;52:2987-90

[104] Wiestler OD,Eibl RH,Aguzzi A.Retrovirus-mediated oncogene transfer into neural transplants.Brain Pathol1992;2:47-59

[105] Wiestler OD,Eibl RH.A new approach to the molecular basis of neoplastic transformation in the brain.Neuropathol Appl Neurobiol1992;18:443-53

[106] Wiestler OD,Eibl RH,Aguzzi A.Oncogene transfer into the brain. Molecular Neuro-oncology and Its Impact on the Clinical Management of Brain Tumors 1994:5-66.

[107] Wiestler OD,Brüstle O,Radner H.Oncogene complementation in transgenic neural transplants.Neuropathology1990;4:304-9

[108] Louis DN,Wesseling P.The 2021 WHO classification of tumors of the central nervous system: a summary.Neuro Oncol2021;23:1231-51 PMCID:PMC8328013

[109] Eibl RH.Liquid biopsy for monitoring medulloblastoma.Extracell Vesicles Circ Nucleic Acids2022;3:263-74

[110] Martínez-Ricarte F,Martínez-Sáez E.Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid.Clin Cancer Res2018;24:2812-9

[111] Miller AM,Pentsova EI.Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid.Nature2019;565:654-8 PMCID:PMC6457907

[112] Mouliere F,Chandrananda D.Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients.EMBO Mol Med2018;10:e9323 PMCID:PMC6284385

[113] Pan Y,Liu Q.Current advances and future perspectives of cerebrospinal fluid biopsy in midline brain malignancies.Curr Treat Options Oncol2019;20:88

[114] Wang Y,Zhang M.Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord.Proc Natl Acad Sci USA2015;112:9704-9 PMCID:PMC4534284

[115] De Mattos-Arruda L,Ng CKY.Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma.Nat Commun2015;6:8839 PMCID:PMC5426516

[116] Guler GD,Ku CJ.Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA.Nat Commun2020;11:5270 PMCID:PMC7572413

[117] Haan D,Guler GD. Validation of a pancreatic cancer detection test in new-onset diabetes using cell-free DNA 5-Hydroxymethylation signatures, 2021. Available from: https://www.medrxiv.org/content/10.1101/2021.12.27.21268450v1 [Last accessed on 27 Jul 2022]

[118] Bluestar Genomics. Liquid biopsy cancer detection. BlueStar Genomics. Available from: https://www.bluestargenomics.com/ [Last accessed on 27 Jul 2022]

[119] The first blood test for colon cancer screening and prevention. Available from: https://cellmaxlife.in/ [Last accessed on 29 Jul 2022]

[120] Home. Circulogene. Available from: https://circulogene.com/ [Last accessed on 27 Jul 2022]

[121] Home. Exact Sciences. Available from: https://www.exactsciences.com/ [Last accessed on 27 Jul 2022]

[122] Foundation Medicine. A World-leading Molecular Insights Company. Available from: https://www.foundationmedicine.com/ [Last accessed on 27 Jul 2022]

[123] Kim ST,Lee SH.Prospective feasibility study for using cell-free circulating tumor DNA-guided therapy in refractory metastatic solid cancers: an interim analysis.JCO Precis Oncol2017;1:PO.16.00059 PMCID:PMC7446388

[124] Liquid Biopsy For All Advanced Solid Tumors. Guardant360® CDx. Available from: https://guardant360cdx.com/ [Last accessed on 27 Jul 2022]

[125] Zheng Z,Zhelyazkova B.Anchored multiplex PCR for targeted next-generation sequencing.Nat Med2014;20:1479-84

[126] Democratizing precision oncology. ArcherDX. Available from: https://archerdx.com/ [Last accessed on 27 Jul 2022]

[127] So MK,Kim JW.Analytical validation of a pan-cancer panel for cell-free assay for the detection of.EGFR2021;11:1022 PMCID:PMC8227964

[128] Scientific TF. Oncomine next-generation sequencing solutions for precision oncology research. Available from: https://www.oncomine.com [Last accessed on 27 Jul 2022]

[129] Welcome to Inivata. A Leader in Liquid Biopsy. Cancer Care Treatment. Available from: https://www.inivata.com/ [Last accessed on 27 Jul 2022]

[130] Natera: A global leader in cfDNA testing. Natera. Available from: https://www.natera.com/ [Last accessed on 27 Jul 2022]

[131] Biocept – Advancing Diagnostics to Improve Cancer Treatments. Available from: https://biocept.com/ [Last accessed on 27 Jul 2022]

[132] van der Leest P,van Noesel CJM.Dutch national round robin trial on plasma-derived circulating cell-free DNA extraction methods routinely used in clinical pathology for molecular tumor profiling.Clin Chem2022;68:963-72

[133] Eibl RH,Moll J.Expression of variant CD44 epitopes in human astrocytic brain tumors.J Neurooncol1995;26:165-70

[134] Home. Australian Clinical Trials. Available from: https://www.australianclinicaltrials.gov.au/ [Last accessed on 27 Jul 2022]

[135] Pax M,Eibl RH,Johannsmann D.Measurements of fast fluctuations of viscoelastic properties with the quartz crystal microbalance.Analyst2005;130:1474-7

[136] Eibl RH.Molecular resolution of cell adhesion forces.IEE Proc Nanobiotechnol2004;151:128-32

[137] Eibl RH. AFM-based adhesion measurements of single receptor-ligand bonds on living cells. In: Pandalai SG, editor. Recent research developments in biophysics. Trivandrum: Transworld Research Network; 2004:235–46. Available from: https://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17751719 [Last accessed on 27 Jul 2022]

[138] Eibl RH.Atomic force microscopy measurements of protein–ligand interactions on living cells. Methods Mol Biol 2005;305:439-50.

[139] Eibl RH.Direct force measurements of receptor–ligand interactions on living cells. In: Bhushan B, Fuchs H, editors. Applied Scanning Probe Methods XII: Characterization. Berlin, Heidelberg: Springer; 2009. pp. 1-31.

[140] Eibl RH.Cell adhesion receptors studied by AFM-Based single-molecule force spectroscopy. In: Bhushan B, editor. Scanning Probe Microscopy in Nanoscience and Nanotechnology 2. Berlin, Heidelberg: Springer; 2011. pp. 197-215.

[141] Eibl RH.Single-molecule studies of integrins by AFM-based force spectroscopy on living cells. In: Bhushan B, editor. Scanning Probe Microscopy in Nanoscience and Nanotechnology 3. Berlin, Heidelberg: Springer; 2013. pp. 137–69.

[142] Eibl RH.Comment on "A method to measure cellular adhesion utilizing a polymer micro-cantilever".Appl Phys Lett2014;104:236103 PMCID:PMC8587856

[143] Eibl RH.Atomic force microscopy measurements of protein-ligand interactions on living cells. In: Ulrich Nienhaus G, editor. Protein-Ligand Interactions: Methods and Applications. Totowa, NJ: Humana Press; 2005. pp. 439-49.

[144] Eibl RH. First measurement of physiologic VLA-4 activation by SDF-1 at the single-molecule level on a living cell. In: Hinterdorfer P, Schütz G, Pohl P, editors. Proceedings of the VIII. Linz Winter Workshop 2006: Advances in Single Molecule Research for Biology and Nanoscience. Linz: Trauner; 2006. pp. 40-3.

[145] Gonzalez-Beltran AN,Ampe C.Community standards for open cell migration data.Gigascience2020;9:giaa041 PMCID:PMC7317087

[146] Wiestler OD,Schneemann M,von Deimling A.Oncogene complementation in fetal brain transplants.Cancer Res1992;52:3760-7

[147] Radner H,Eibl RH.Tumor induction by ras and myc oncogenes in fetal and neonatal brain: modulating effects of developmental stage and retroviral dose.Acta Neuropathol1993;86:456-65

[148] Rack B,Jückstock J.SUCCESS Study GroupCirculating tumor cells predict survival in early average-to-high risk breast cancer patients.J Natl Cancer Inst2014;106:dju066 PMCID:PMC4112925